Pipeline

Discovery

Lead Opt.

IND-Enabling

Phase 1

Phase 2

AEAr Agonists

Acute and Chronic Pain

SBS-1000 IV/SC

72%

SBS-147 Oral

53%

MOR Partial Agonist / DOR Antagonist

Opioid Use Disorder / Opioid Withdrawal Syndrome

SBS-226 Oral

32%

Sigma Antagonist / DAT Inhibitor

Stimulant Use Disorder

SBS-518 Oral

32%

AEAr Agonists

Acute and Chronic Pain

SBS-1000 IV/SC | Phase 1

72%

SBS-147 Oral | CMC and IND-enabling Studies

62%

MOR Partial Agonist / DOR Antagonist

Opioid Use Disorder / Opioid Withdrawal Syndrome

SBS-226 Oral | Lead Selection

32%

Irreversible MOR Antagonists

Opioid Overdose

SBS-226 Oral | Lead Selection

32%

Sigma Antagonist / DAT Inhibitor

Stimulant Use Disorder

SBS-518 | Lead Selection

32%

Arylepoxamide Receptor (AEAr) Agonists

Acute and Chronic Pain

SBS-1000 (IV/SC) and SBS-147 (oral) are first-in-class arylepoxamides which bind and active the newly discovered receptor, the AEAr. In preclinical studies, arylepoxamides demonstrate potent analgesia for acute and chronic pain and a clean safety profile lacking respiratory depression, physical dependence, and reward behavior.

SBS-1000 | Phase 1
SBS-147 | CMC and IND-enabling Studies

MOR Partial Agonist / DOR Antagonist

Opioid Use Disorder (OUD) and Opioid Withdrawal Syndrome (OWS)

SBS-226 is a first-in-class MOR partial agonist / DOR antagonist being developed for OUD and OWS. Structurally, it is a derivative of mitragynine pseudoindoxyl – one of the primary alkaloids in Kratom. SBS-226 is a new chemical entity (NCE) synthesized and developed in the Majumdar Lab. Preclinically, SBS-226 can ameliorate opioid withdrawal but does not demonstrate abuse potential, respiratory depression, or physical dependence.

SBS-226 | Lead Optimization

Irreversible MOR Antagonists

Opioid Overdose

SBS-371 is a first in class irreversible MOR antagonist being developed for the acute treatment and prophylaxis of opioid overdose. The opioid epidemic has transformed to a fentanyl epidemic and urgently demands more potent, longer lasting MOR antagonists. Preclinically, SBS-371 can prevent and reverse a synthetic opioid overdose (e.g. fentanyl and fentanyl derivatives).

SBS-371 | Lead Optimization

Sigma Antagonist / DAT Inhibitor

Stimulant Use Disorder (Cocaine and Methamphetamine)

SBS-518 is a first-in-class dual acting sigma antagonist / dopamine active transporter (DAT) inhibitor being developed for stimulant use disorder (StUD). There are ~3.2 M people with StUD and ~57 K StUD overdose related deaths per year. Preclinically, SBS-518 reduces cocaine self-administration and reduces cocaine-induced extracellular dopamine increases.

SBS-518 | Lead Optimization